Signal Genetics
Carlsbad
About Signal Genetics
Signal Genetics, Inc., is a commercial-stage, molecular diagnostics company providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences (UAMS). More than 30 years of clinical research on nearly 10,000 multiple myeloma patients who received their care at UAMS went into the development of Signal Genetics’ flagship product, MyPRS® (Myeloma Prognostic Risk Signature).
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $25.0M
- Funding stage: M&A
- Last round: Convertible Note (Jan 2011)
- Ticker: nasdaq:SGNL
- Website: signalgenetics.com
- Phone: +1 760-537-4100
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Innovation Management
Social Profiles
Canonical: https://fsome.com/organization/signal-genetics-2324848 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.